Y. Ostapenko

机构：National Cancer Institute

发表论文 18 篇 · 总被引 373 次 · h-index 3

代表论文

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 329)
• SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2023 · Annals of Oncology · 被引 21)
• Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial (2025 · ESMO Open · 被引 5)
• OA02.05 Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA (2024 · Journal of Thoracic Oncology · 被引 3)
• INTRA-ARTERIAL CHEMOTHERAPY AS A CLINICAL OPTION FOR METASTATIC COLORECTAL CANCER: CONVERSION OF INOPERABLE LIVER METASTASES TO OPERABLE ILLUSTRATED WITH A CLINICAL CASE (2024 · Experimental Oncology · 被引 2)
• P-71 Overcoming chemoresistance in patients with metastatic colorectal cancer using hepatic arterial infusion (2023 · Annals of Oncology · 被引 2)